Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats

Chihiro Suzuki, Masafumi Takahashi, Hajime Morimoto, Atsushi Izawa, Hirohiko Ise, Minoru Hongo, Yasushi Hoshikawa, Takayuki Ito, Hiroshi Miyashita, Eiji Kobayashi, Kazuyuki Shimada, Uichi Ikeda

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is characterized by abnormal proliferation of smooth muscle cells (SMCs), leading to occlusion of pulmonary arterioles, right ventricular (RV) hypertrophy, and death. We investigated whether mycophenolate mofetil (MMF), a potent immunosuppresssant, prevents the development of monocrotaline (MCT)-induced PAH in rats. MMF effectively decreased RV systolic pressure and RV hypertrophy, and reduced the medial thickness of pulmonary arteries. MMF significantly inhibited the number of proliferating cell nuclear antigen (PCNA)-positive cells, infiltration of macrophages, and expression of P-selectin and interleukin-6 on the endothelium of pulmonary arteries. The infiltration of T cells and mast cells was not affected by MMF. In vitro experiments revealed that mycophenolic acid (MPA), an active metabolite of MMF, dose-dependently inhibited proliferation of human pulmonary arterial SMCs. MMF attenuated the development of PAH through its anti-inflammatory and anti-proliferative properties. These findings provide new insight into the potential role of immunosuppressants in the treatment of PAH.

Original languageEnglish
Pages (from-to)781-788
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume349
Issue number2
DOIs
Publication statusPublished - 20-10-2006

Fingerprint

Mycophenolic Acid
Pulmonary Hypertension
Rats
Right Ventricular Hypertrophy
Infiltration
Pulmonary Artery
Smooth Muscle Myocytes
Muscle
Cells
Monocrotaline
Lung
P-Selectin
T-cells
Macrophages
Proliferating Cell Nuclear Antigen
Arterioles
Ventricular Pressure
Immunosuppressive Agents
Metabolites
Mast Cells

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Suzuki, C., Takahashi, M., Morimoto, H., Izawa, A., Ise, H., Hongo, M., ... Ikeda, U. (2006). Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochemical and Biophysical Research Communications, 349(2), 781-788. https://doi.org/10.1016/j.bbrc.2006.08.109
Suzuki, Chihiro ; Takahashi, Masafumi ; Morimoto, Hajime ; Izawa, Atsushi ; Ise, Hirohiko ; Hongo, Minoru ; Hoshikawa, Yasushi ; Ito, Takayuki ; Miyashita, Hiroshi ; Kobayashi, Eiji ; Shimada, Kazuyuki ; Ikeda, Uichi. / Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 349, No. 2. pp. 781-788.
@article{292985e8b83c4abea30485fcb4283e8f,
title = "Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats",
abstract = "Pulmonary arterial hypertension (PAH) is characterized by abnormal proliferation of smooth muscle cells (SMCs), leading to occlusion of pulmonary arterioles, right ventricular (RV) hypertrophy, and death. We investigated whether mycophenolate mofetil (MMF), a potent immunosuppresssant, prevents the development of monocrotaline (MCT)-induced PAH in rats. MMF effectively decreased RV systolic pressure and RV hypertrophy, and reduced the medial thickness of pulmonary arteries. MMF significantly inhibited the number of proliferating cell nuclear antigen (PCNA)-positive cells, infiltration of macrophages, and expression of P-selectin and interleukin-6 on the endothelium of pulmonary arteries. The infiltration of T cells and mast cells was not affected by MMF. In vitro experiments revealed that mycophenolic acid (MPA), an active metabolite of MMF, dose-dependently inhibited proliferation of human pulmonary arterial SMCs. MMF attenuated the development of PAH through its anti-inflammatory and anti-proliferative properties. These findings provide new insight into the potential role of immunosuppressants in the treatment of PAH.",
author = "Chihiro Suzuki and Masafumi Takahashi and Hajime Morimoto and Atsushi Izawa and Hirohiko Ise and Minoru Hongo and Yasushi Hoshikawa and Takayuki Ito and Hiroshi Miyashita and Eiji Kobayashi and Kazuyuki Shimada and Uichi Ikeda",
year = "2006",
month = "10",
day = "20",
doi = "10.1016/j.bbrc.2006.08.109",
language = "English",
volume = "349",
pages = "781--788",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

Suzuki, C, Takahashi, M, Morimoto, H, Izawa, A, Ise, H, Hongo, M, Hoshikawa, Y, Ito, T, Miyashita, H, Kobayashi, E, Shimada, K & Ikeda, U 2006, 'Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats', Biochemical and Biophysical Research Communications, vol. 349, no. 2, pp. 781-788. https://doi.org/10.1016/j.bbrc.2006.08.109

Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. / Suzuki, Chihiro; Takahashi, Masafumi; Morimoto, Hajime; Izawa, Atsushi; Ise, Hirohiko; Hongo, Minoru; Hoshikawa, Yasushi; Ito, Takayuki; Miyashita, Hiroshi; Kobayashi, Eiji; Shimada, Kazuyuki; Ikeda, Uichi.

In: Biochemical and Biophysical Research Communications, Vol. 349, No. 2, 20.10.2006, p. 781-788.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats

AU - Suzuki, Chihiro

AU - Takahashi, Masafumi

AU - Morimoto, Hajime

AU - Izawa, Atsushi

AU - Ise, Hirohiko

AU - Hongo, Minoru

AU - Hoshikawa, Yasushi

AU - Ito, Takayuki

AU - Miyashita, Hiroshi

AU - Kobayashi, Eiji

AU - Shimada, Kazuyuki

AU - Ikeda, Uichi

PY - 2006/10/20

Y1 - 2006/10/20

N2 - Pulmonary arterial hypertension (PAH) is characterized by abnormal proliferation of smooth muscle cells (SMCs), leading to occlusion of pulmonary arterioles, right ventricular (RV) hypertrophy, and death. We investigated whether mycophenolate mofetil (MMF), a potent immunosuppresssant, prevents the development of monocrotaline (MCT)-induced PAH in rats. MMF effectively decreased RV systolic pressure and RV hypertrophy, and reduced the medial thickness of pulmonary arteries. MMF significantly inhibited the number of proliferating cell nuclear antigen (PCNA)-positive cells, infiltration of macrophages, and expression of P-selectin and interleukin-6 on the endothelium of pulmonary arteries. The infiltration of T cells and mast cells was not affected by MMF. In vitro experiments revealed that mycophenolic acid (MPA), an active metabolite of MMF, dose-dependently inhibited proliferation of human pulmonary arterial SMCs. MMF attenuated the development of PAH through its anti-inflammatory and anti-proliferative properties. These findings provide new insight into the potential role of immunosuppressants in the treatment of PAH.

AB - Pulmonary arterial hypertension (PAH) is characterized by abnormal proliferation of smooth muscle cells (SMCs), leading to occlusion of pulmonary arterioles, right ventricular (RV) hypertrophy, and death. We investigated whether mycophenolate mofetil (MMF), a potent immunosuppresssant, prevents the development of monocrotaline (MCT)-induced PAH in rats. MMF effectively decreased RV systolic pressure and RV hypertrophy, and reduced the medial thickness of pulmonary arteries. MMF significantly inhibited the number of proliferating cell nuclear antigen (PCNA)-positive cells, infiltration of macrophages, and expression of P-selectin and interleukin-6 on the endothelium of pulmonary arteries. The infiltration of T cells and mast cells was not affected by MMF. In vitro experiments revealed that mycophenolic acid (MPA), an active metabolite of MMF, dose-dependently inhibited proliferation of human pulmonary arterial SMCs. MMF attenuated the development of PAH through its anti-inflammatory and anti-proliferative properties. These findings provide new insight into the potential role of immunosuppressants in the treatment of PAH.

UR - http://www.scopus.com/inward/record.url?scp=33748439778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748439778&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.08.109

DO - 10.1016/j.bbrc.2006.08.109

M3 - Article

C2 - 16956581

AN - SCOPUS:33748439778

VL - 349

SP - 781

EP - 788

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -